John Arcaroli
Concepts (369)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 19 | 2018 | 844 | 2.360 |
Why?
| | Xenograft Model Antitumor Assays | 21 | 2024 | 928 | 1.390 |
Why?
| | Antineoplastic Agents | 17 | 2018 | 2192 | 1.290 |
Why?
| | Drug Resistance, Neoplasm | 7 | 2016 | 881 | 0.970 |
Why?
| | Quinazolines | 4 | 2012 | 266 | 0.960 |
Why?
| | Benzodioxoles | 3 | 2012 | 158 | 0.920 |
Why?
| | Camptothecin | 4 | 2016 | 140 | 0.850 |
Why?
| | Receptor, Notch1 | 3 | 2015 | 64 | 0.820 |
Why?
| | Aldehyde Dehydrogenase | 6 | 2017 | 99 | 0.820 |
Why?
| | Mice, Nude | 16 | 2024 | 682 | 0.770 |
Why?
| | Haplotypes | 4 | 2012 | 490 | 0.720 |
Why?
| | Phosphatidylinositol 3-Kinases | 10 | 2018 | 379 | 0.680 |
Why?
| | Gene Dosage | 3 | 2015 | 148 | 0.610 |
Why?
| | Wnt Signaling Pathway | 5 | 2024 | 210 | 0.600 |
Why?
| | Neutrophils | 13 | 2007 | 1134 | 0.580 |
Why?
| | src-Family Kinases | 3 | 2017 | 93 | 0.570 |
Why?
| | Amyloid Precursor Protein Secretases | 3 | 2014 | 77 | 0.570 |
Why?
| | Endotoxemia | 9 | 2004 | 87 | 0.560 |
Why?
| | Pancreatic Neoplasms | 6 | 2024 | 918 | 0.560 |
Why?
| | Anilides | 2 | 2018 | 84 | 0.550 |
Why?
| | Enzyme Inhibitors | 5 | 2016 | 824 | 0.550 |
Why?
| | Protein Kinase Inhibitors | 9 | 2018 | 968 | 0.530 |
Why?
| | Biomarkers, Tumor | 9 | 2018 | 1313 | 0.510 |
Why?
| | Mice | 41 | 2024 | 18329 | 0.500 |
Why?
| | Acute Lung Injury | 2 | 2011 | 302 | 0.490 |
Why?
| | Tankyrases | 1 | 2016 | 13 | 0.480 |
Why?
| | Receptors, Notch | 2 | 2015 | 92 | 0.480 |
Why?
| | Cell Line, Tumor | 21 | 2024 | 3539 | 0.470 |
Why?
| | Pyridines | 4 | 2018 | 605 | 0.460 |
Why?
| | Drug Discovery | 1 | 2016 | 154 | 0.450 |
Why?
| | Polymorphism, Genetic | 3 | 2007 | 612 | 0.450 |
Why?
| | NF-kappa B | 13 | 2007 | 661 | 0.440 |
Why?
| | 3' Untranslated Regions | 2 | 2012 | 152 | 0.430 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 183 | 0.420 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 85 | 0.420 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2014 | 75 | 0.410 |
Why?
| | Tetrahydronaphthalenes | 1 | 2013 | 31 | 0.390 |
Why?
| | Valine | 1 | 2013 | 80 | 0.390 |
Why?
| | Animals | 44 | 2024 | 38030 | 0.370 |
Why?
| | Mitogen-Activated Protein Kinases | 7 | 2014 | 292 | 0.370 |
Why?
| | Lipopolysaccharides | 9 | 2007 | 863 | 0.340 |
Why?
| | Sepsis | 3 | 2007 | 640 | 0.340 |
Why?
| | Signal Transduction | 17 | 2018 | 5221 | 0.340 |
Why?
| | Superoxide Dismutase | 3 | 2008 | 301 | 0.330 |
Why?
| | Proto-Oncogene Proteins | 8 | 2018 | 623 | 0.320 |
Why?
| | Urokinase-Type Plasminogen Activator | 2 | 2007 | 24 | 0.320 |
Why?
| | Cell Proliferation | 13 | 2024 | 2494 | 0.310 |
Why?
| | Interleukins | 1 | 2011 | 248 | 0.300 |
Why?
| | Neoplasm Metastasis | 4 | 2016 | 688 | 0.300 |
Why?
| | Hemorrhage | 6 | 2004 | 809 | 0.280 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 3 | 2014 | 108 | 0.280 |
Why?
| | Heterografts | 3 | 2018 | 143 | 0.280 |
Why?
| | Apoptosis | 11 | 2018 | 2430 | 0.270 |
Why?
| | HCT116 Cells | 4 | 2018 | 78 | 0.270 |
Why?
| | SOXB1 Transcription Factors | 2 | 2018 | 67 | 0.250 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2024 | 291 | 0.250 |
Why?
| | Azepines | 2 | 2018 | 107 | 0.250 |
Why?
| | Promoter Regions, Genetic | 1 | 2011 | 1255 | 0.240 |
Why?
| | Benzimidazoles | 3 | 2013 | 190 | 0.240 |
Why?
| | Mutation | 3 | 2012 | 4085 | 0.240 |
Why?
| | Immunoblotting | 5 | 2015 | 300 | 0.240 |
Why?
| | Receptors, Interleukin-1 | 1 | 2006 | 213 | 0.220 |
Why?
| | Neutrophil Activation | 5 | 2003 | 85 | 0.220 |
Why?
| | beta Catenin | 3 | 2016 | 252 | 0.220 |
Why?
| | Oligonucleotide Array Sequence Analysis | 6 | 2015 | 758 | 0.210 |
Why?
| | Humans | 46 | 2024 | 144261 | 0.210 |
Why?
| | TOR Serine-Threonine Kinases | 4 | 2018 | 449 | 0.210 |
Why?
| | Pyrimidines | 2 | 2018 | 532 | 0.200 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2006 | 459 | 0.200 |
Why?
| | Mice, Inbred BALB C | 10 | 2003 | 1253 | 0.200 |
Why?
| | Adrenergic alpha-Antagonists | 2 | 2002 | 34 | 0.200 |
Why?
| | Proto-Oncogene Proteins c-akt | 8 | 2018 | 436 | 0.200 |
Why?
| | Colonic Neoplasms | 2 | 2016 | 259 | 0.190 |
Why?
| | Adrenergic alpha-Agonists | 1 | 2002 | 27 | 0.190 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 2002 | 45 | 0.190 |
Why?
| | Genetic Predisposition to Disease | 1 | 2011 | 2359 | 0.180 |
Why?
| | Neuroimmunomodulation | 1 | 2002 | 68 | 0.180 |
Why?
| | ras Proteins | 3 | 2013 | 150 | 0.180 |
Why?
| | Adrenergic beta-Agonists | 1 | 2002 | 91 | 0.180 |
Why?
| | Female | 24 | 2018 | 77976 | 0.180 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2002 | 250 | 0.180 |
Why?
| | Aged | 11 | 2016 | 25850 | 0.170 |
Why?
| | Middle Aged | 12 | 2016 | 35762 | 0.160 |
Why?
| | Hemoptysis | 1 | 2000 | 36 | 0.160 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2011 | 2143 | 0.160 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2012 | 322 | 0.160 |
Why?
| | Cytokines | 4 | 2005 | 2061 | 0.150 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2016 | 641 | 0.150 |
Why?
| | Head and Neck Neoplasms | 2 | 2016 | 556 | 0.150 |
Why?
| | Adult | 11 | 2016 | 40262 | 0.150 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2018 | 339 | 0.150 |
Why?
| | DNA Topoisomerases, Type II | 2 | 2016 | 47 | 0.140 |
Why?
| | Male | 24 | 2016 | 72035 | 0.140 |
Why?
| | CDC2 Protein Kinase | 1 | 2018 | 27 | 0.140 |
Why?
| | Transplantation, Heterologous | 2 | 2016 | 193 | 0.140 |
Why?
| | MAP Kinase Kinase Kinases | 2 | 2015 | 70 | 0.140 |
Why?
| | Oncogene Proteins v-abl | 1 | 2017 | 5 | 0.140 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 4 | 2003 | 145 | 0.140 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 3 | 2010 | 128 | 0.130 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 6 | 2007 | 266 | 0.130 |
Why?
| | Immunohistochemistry | 5 | 2017 | 1715 | 0.130 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 5 | 2016 | 253 | 0.130 |
Why?
| | Dasatinib | 1 | 2017 | 57 | 0.130 |
Why?
| | Gene Expression Profiling | 4 | 2018 | 1782 | 0.130 |
Why?
| | Case-Control Studies | 3 | 2011 | 3592 | 0.130 |
Why?
| | Antigens, Neoplasm | 2 | 2016 | 271 | 0.130 |
Why?
| | Angiogenesis Inhibitors | 2 | 2018 | 236 | 0.130 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2015 | 381 | 0.130 |
Why?
| | Neovascularization, Pathologic | 2 | 2018 | 286 | 0.130 |
Why?
| | Phosphatidylinositol 3-Kinase | 1 | 2016 | 25 | 0.120 |
Why?
| | Receptors, Cell Surface | 2 | 2012 | 377 | 0.120 |
Why?
| | Axin Protein | 1 | 2016 | 19 | 0.120 |
Why?
| | Corynebacterium | 1 | 2017 | 49 | 0.120 |
Why?
| | Adenocarcinoma | 2 | 2014 | 927 | 0.120 |
Why?
| | Aurora Kinase A | 1 | 2016 | 62 | 0.120 |
Why?
| | Corynebacterium Infections | 1 | 2017 | 42 | 0.120 |
Why?
| | Neoplasms, Experimental | 1 | 2017 | 173 | 0.120 |
Why?
| | Transcription Factor 7-Like 2 Protein | 1 | 2016 | 26 | 0.120 |
Why?
| | Cell Cycle | 5 | 2018 | 596 | 0.120 |
Why?
| | Neoplastic Stem Cells | 2 | 2018 | 412 | 0.120 |
Why?
| | Autophagy | 1 | 2018 | 285 | 0.120 |
Why?
| | Genotype | 3 | 2012 | 1833 | 0.120 |
Why?
| | Serrate-Jagged Proteins | 1 | 2015 | 27 | 0.120 |
Why?
| | Jagged-1 Protein | 1 | 2015 | 22 | 0.120 |
Why?
| | RNA, Small Interfering | 2 | 2015 | 634 | 0.110 |
Why?
| | Drug Synergism | 2 | 2014 | 357 | 0.110 |
Why?
| | Gene Duplication | 1 | 2015 | 67 | 0.110 |
Why?
| | Retinaldehyde | 1 | 2015 | 4 | 0.110 |
Why?
| | RNA, Messenger | 5 | 2016 | 2829 | 0.110 |
Why?
| | HMGB1 Protein | 2 | 2007 | 51 | 0.110 |
Why?
| | Acetaldehyde | 1 | 2015 | 17 | 0.110 |
Why?
| | Neoplasms | 3 | 2016 | 2870 | 0.110 |
Why?
| | Chemokines | 5 | 2003 | 218 | 0.110 |
Why?
| | Aged, 80 and over | 5 | 2014 | 8243 | 0.110 |
Why?
| | Pyrimidinones | 1 | 2015 | 126 | 0.110 |
Why?
| | Acridines | 1 | 2014 | 9 | 0.110 |
Why?
| | Neoplasm Transplantation | 4 | 2016 | 251 | 0.110 |
Why?
| | Chemokine CXCL2 | 4 | 2001 | 41 | 0.110 |
Why?
| | Topoisomerase II Inhibitors | 1 | 2014 | 26 | 0.110 |
Why?
| | Pyrazoles | 1 | 2018 | 509 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2014 | 1953 | 0.100 |
Why?
| | Wnt Proteins | 1 | 2015 | 133 | 0.100 |
Why?
| | Benzazepines | 1 | 2014 | 35 | 0.100 |
Why?
| | Calcium-Binding Proteins | 1 | 2015 | 219 | 0.100 |
Why?
| | Pyridones | 1 | 2015 | 198 | 0.100 |
Why?
| | Gene Expression Regulation | 2 | 2007 | 2603 | 0.100 |
Why?
| | Cell Cycle Proteins | 1 | 2018 | 628 | 0.100 |
Why?
| | Respiration, Artificial | 2 | 2011 | 707 | 0.100 |
Why?
| | Cell Growth Processes | 1 | 2013 | 50 | 0.100 |
Why?
| | Insulin-Like Growth Factor Binding Protein 2 | 1 | 2012 | 8 | 0.090 |
Why?
| | Tumor Suppressor Proteins | 1 | 2015 | 321 | 0.090 |
Why?
| | Enzyme Activation | 6 | 2003 | 765 | 0.090 |
Why?
| | Cellular Senescence | 1 | 2015 | 226 | 0.090 |
Why?
| | Random Allocation | 1 | 2013 | 363 | 0.090 |
Why?
| | DNA-Binding Proteins | 3 | 2016 | 1497 | 0.090 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 336 | 0.090 |
Why?
| | Molecular Targeted Therapy | 1 | 2015 | 431 | 0.090 |
Why?
| | Aldehyde Dehydrogenase, Mitochondrial | 3 | 2017 | 23 | 0.090 |
Why?
| | Disease Models, Animal | 4 | 2018 | 4556 | 0.090 |
Why?
| | Chemokine CXCL12 | 1 | 2012 | 89 | 0.090 |
Why?
| | Cyclosporine | 1 | 2013 | 265 | 0.090 |
Why?
| | Receptors, CXCR4 | 1 | 2012 | 91 | 0.090 |
Why?
| | Linkage Disequilibrium | 2 | 2012 | 246 | 0.090 |
Why?
| | Immunoprecipitation | 1 | 2012 | 151 | 0.090 |
Why?
| | Melanoma | 1 | 2018 | 760 | 0.090 |
Why?
| | Hydroxamic Acids | 1 | 2011 | 94 | 0.090 |
Why?
| | Lung Diseases | 3 | 2004 | 787 | 0.090 |
Why?
| | Lung | 8 | 2004 | 4108 | 0.090 |
Why?
| | Genetic Markers | 1 | 2012 | 331 | 0.080 |
Why?
| | Peroxidase | 2 | 2002 | 168 | 0.080 |
Why?
| | Prognosis | 3 | 2015 | 4278 | 0.080 |
Why?
| | Drug Design | 1 | 2012 | 173 | 0.080 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 164 | 0.080 |
Why?
| | Sirolimus | 1 | 2012 | 281 | 0.080 |
Why?
| | Genetic Association Studies | 1 | 2012 | 372 | 0.080 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2011 | 220 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2013 | 985 | 0.080 |
Why?
| | Administration, Oral | 1 | 2012 | 847 | 0.080 |
Why?
| | Phosphorylation | 3 | 2018 | 1732 | 0.080 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2004 | 1217 | 0.080 |
Why?
| | Cetuximab | 3 | 2016 | 111 | 0.080 |
Why?
| | Cell Separation | 1 | 2010 | 307 | 0.070 |
Why?
| | Membrane Proteins | 1 | 2015 | 1165 | 0.070 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 2 | 2018 | 44 | 0.070 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2016 | 1455 | 0.070 |
Why?
| | Antibodies, Monoclonal | 1 | 2015 | 1519 | 0.070 |
Why?
| | Models, Statistical | 1 | 2012 | 677 | 0.070 |
Why?
| | Genetic Variation | 2 | 2012 | 982 | 0.070 |
Why?
| | Cells, Cultured | 6 | 2007 | 4146 | 0.060 |
Why?
| | HT29 Cells | 2 | 2018 | 37 | 0.060 |
Why?
| | Gene Expression | 2 | 2003 | 1487 | 0.060 |
Why?
| | Europe | 1 | 2007 | 412 | 0.060 |
Why?
| | ErbB Receptors | 3 | 2016 | 627 | 0.060 |
Why?
| | Flow Cytometry | 1 | 2010 | 1172 | 0.060 |
Why?
| | Thymine | 1 | 2006 | 17 | 0.060 |
Why?
| | Clinical Trials as Topic | 2 | 2015 | 1050 | 0.060 |
Why?
| | Genome, Human | 1 | 2008 | 422 | 0.060 |
Why?
| | Cytosine | 1 | 2006 | 51 | 0.060 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2006 | 40 | 0.060 |
Why?
| | Phentolamine | 2 | 2002 | 20 | 0.060 |
Why?
| | Inflammation Mediators | 2 | 2006 | 508 | 0.060 |
Why?
| | Tumor Burden | 2 | 2018 | 319 | 0.060 |
Why?
| | MicroRNAs | 1 | 2012 | 700 | 0.060 |
Why?
| | Homozygote | 1 | 2006 | 199 | 0.060 |
Why?
| | MAP Kinase Kinase 2 | 2 | 2002 | 29 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 981 | 0.060 |
Why?
| | Translocation, Genetic | 1 | 2006 | 115 | 0.060 |
Why?
| | Propranolol | 2 | 2002 | 44 | 0.060 |
Why?
| | MAP Kinase Kinase 1 | 2 | 2002 | 71 | 0.060 |
Why?
| | Survival Analysis | 1 | 2008 | 1382 | 0.060 |
Why?
| | Spheroids, Cellular | 2 | 2016 | 73 | 0.060 |
Why?
| | Cell Nucleus | 2 | 2006 | 618 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 2 | 2002 | 138 | 0.060 |
Why?
| | Adolescent | 3 | 2011 | 22281 | 0.050 |
Why?
| | Introns | 1 | 2006 | 254 | 0.050 |
Why?
| | Heat-Shock Proteins | 1 | 2005 | 138 | 0.050 |
Why?
| | Exons | 1 | 2006 | 358 | 0.050 |
Why?
| | Models, Biological | 2 | 2018 | 1820 | 0.050 |
Why?
| | Bone Marrow Cells | 2 | 2003 | 320 | 0.050 |
Why?
| | Neoplasm Invasiveness | 2 | 2016 | 508 | 0.050 |
Why?
| | Shock, Septic | 1 | 2006 | 215 | 0.050 |
Why?
| | Positron-Emission Tomography | 2 | 2018 | 323 | 0.050 |
Why?
| | Cause of Death | 1 | 2006 | 464 | 0.050 |
Why?
| | Oxidants | 1 | 2003 | 103 | 0.050 |
Why?
| | Models, Genetic | 1 | 2005 | 535 | 0.050 |
Why?
| | Paclitaxel | 1 | 2024 | 255 | 0.050 |
Why?
| | Ribosomal Protein S6 Kinases | 1 | 2002 | 24 | 0.050 |
Why?
| | Brimonidine Tartrate | 1 | 2002 | 10 | 0.050 |
Why?
| | Deoxycytidine | 1 | 2024 | 221 | 0.050 |
Why?
| | Phenylephrine | 1 | 2002 | 75 | 0.050 |
Why?
| | RNA Interference | 2 | 2016 | 476 | 0.050 |
Why?
| | Organoids | 1 | 2024 | 141 | 0.050 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2002 | 433 | 0.050 |
Why?
| | Isoenzymes | 1 | 2003 | 299 | 0.050 |
Why?
| | Quinoxalines | 1 | 2002 | 65 | 0.050 |
Why?
| | Hydrogen Peroxide | 1 | 2003 | 336 | 0.040 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2002 | 125 | 0.040 |
Why?
| | Transcription, Genetic | 2 | 2006 | 1495 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2637 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 496 | 0.040 |
Why?
| | Free Radical Scavengers | 1 | 2001 | 81 | 0.040 |
Why?
| | Neoplasm Proteins | 3 | 2016 | 442 | 0.040 |
Why?
| | High Mobility Group Proteins | 1 | 2000 | 45 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2002 | 309 | 0.040 |
Why?
| | Imidazoles | 1 | 2001 | 254 | 0.040 |
Why?
| | Interleukin-1 | 2 | 2000 | 961 | 0.040 |
Why?
| | Neutropenia | 1 | 2000 | 155 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2002 | 477 | 0.040 |
Why?
| | Nuclear Proteins | 2 | 2001 | 748 | 0.040 |
Why?
| | Transcriptome | 2 | 2016 | 1044 | 0.040 |
Why?
| | Adjuvants, Immunologic | 1 | 2000 | 245 | 0.040 |
Why?
| | Trans-Activators | 1 | 2001 | 405 | 0.040 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2018 | 24 | 0.040 |
Why?
| | Colorado | 1 | 2008 | 4562 | 0.030 |
Why?
| | 4-Aminobenzoic Acid | 1 | 2018 | 8 | 0.030 |
Why?
| | Up-Regulation | 2 | 2016 | 851 | 0.030 |
Why?
| | Biomarkers | 1 | 2008 | 4254 | 0.030 |
Why?
| | Protein Transport | 1 | 2018 | 441 | 0.030 |
Why?
| | Pneumonia | 1 | 2003 | 630 | 0.030 |
Why?
| | Retinal Dehydrogenase | 1 | 2016 | 29 | 0.030 |
Why?
| | Inhibitory Concentration 50 | 1 | 2016 | 91 | 0.030 |
Why?
| | Blotting, Western | 2 | 2013 | 1187 | 0.030 |
Why?
| | Hyaluronan Receptors | 1 | 2016 | 102 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 112 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2016 | 50 | 0.030 |
Why?
| | Protein Interaction Maps | 1 | 2016 | 51 | 0.030 |
Why?
| | Papillomaviridae | 1 | 2016 | 115 | 0.030 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2016 | 191 | 0.030 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2016 | 139 | 0.030 |
Why?
| | Mice, Inbred C57BL | 4 | 2015 | 5988 | 0.030 |
Why?
| | S-Phase Kinase-Associated Proteins | 1 | 2015 | 20 | 0.030 |
Why?
| | Prospective Studies | 1 | 2007 | 7970 | 0.030 |
Why?
| | Diphenylamine | 1 | 2014 | 8 | 0.030 |
Why?
| | Cadherins | 1 | 2016 | 200 | 0.030 |
Why?
| | Iloprost | 1 | 2015 | 44 | 0.030 |
Why?
| | Acid Phosphatase | 1 | 2014 | 14 | 0.030 |
Why?
| | Cell Division | 1 | 2016 | 766 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2016 | 919 | 0.030 |
Why?
| | Rhodamines | 1 | 2014 | 21 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2016 | 269 | 0.030 |
Why?
| | G2 Phase | 1 | 2014 | 39 | 0.030 |
Why?
| | Young Adult | 1 | 2011 | 13990 | 0.030 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2016 | 219 | 0.030 |
Why?
| | Inflammation | 1 | 2005 | 2877 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2016 | 442 | 0.030 |
Why?
| | Tretinoin | 1 | 2015 | 124 | 0.030 |
Why?
| | Benzamides | 1 | 2014 | 224 | 0.030 |
Why?
| | Transfection | 1 | 2016 | 938 | 0.020 |
Why?
| | Receptor, Notch2 | 1 | 2013 | 15 | 0.020 |
Why?
| | Antigens, CD | 1 | 2016 | 555 | 0.020 |
Why?
| | Gonanes | 1 | 2013 | 28 | 0.020 |
Why?
| | Alphapapillomavirus | 1 | 2013 | 35 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2011 | 17009 | 0.020 |
Why?
| | Receptors, CXCR | 1 | 2012 | 5 | 0.020 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2003 | 39 | 0.020 |
Why?
| | Erlotinib Hydrochloride | 1 | 2012 | 72 | 0.020 |
Why?
| | Cyclin D1 | 1 | 2012 | 61 | 0.020 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2016 | 529 | 0.020 |
Why?
| | Active Transport, Cell Nucleus | 2 | 2003 | 121 | 0.020 |
Why?
| | Protein Binding | 1 | 2018 | 2270 | 0.020 |
Why?
| | Mice, Inbred C3H | 2 | 2004 | 251 | 0.020 |
Why?
| | Computers | 1 | 2012 | 67 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2014 | 768 | 0.020 |
Why?
| | Fluorocarbons | 1 | 2014 | 143 | 0.020 |
Why?
| | Maximum Tolerated Dose | 1 | 2012 | 212 | 0.020 |
Why?
| | Niacinamide | 1 | 2012 | 86 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2012 | 327 | 0.020 |
Why?
| | Phenylurea Compounds | 1 | 2012 | 112 | 0.020 |
Why?
| | Injections, Intraperitoneal | 2 | 2001 | 116 | 0.020 |
Why?
| | Calcium Signaling | 1 | 2013 | 251 | 0.020 |
Why?
| | Mice, Knockout | 3 | 2003 | 3119 | 0.020 |
Why?
| | Xanthine Oxidase | 2 | 2001 | 79 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2003 | 240 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2012 | 167 | 0.020 |
Why?
| | Acute Disease | 2 | 2004 | 1028 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2011 | 519 | 0.020 |
Why?
| | United States | 1 | 2007 | 15876 | 0.020 |
Why?
| | Ligands | 1 | 2011 | 673 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2012 | 557 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2011 | 346 | 0.020 |
Why?
| | Models, Molecular | 1 | 2014 | 1618 | 0.020 |
Why?
| | Survival Rate | 1 | 2014 | 2088 | 0.020 |
Why?
| | Computational Biology | 1 | 2013 | 680 | 0.020 |
Why?
| | Tumor Microenvironment | 1 | 2012 | 732 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 2026 | 0.020 |
Why?
| | Adiposity | 1 | 2012 | 541 | 0.020 |
Why?
| | Calcium | 1 | 2013 | 1182 | 0.020 |
Why?
| | Mice, Transgenic | 2 | 2003 | 2182 | 0.020 |
Why?
| | Cell Movement | 1 | 2011 | 965 | 0.020 |
Why?
| | Oxidative Stress | 2 | 2003 | 1339 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3857 | 0.010 |
Why?
| | Neutrophil Infiltration | 1 | 2004 | 104 | 0.010 |
Why?
| | Permeability | 1 | 2004 | 168 | 0.010 |
Why?
| | Transcription Factor AP-1 | 1 | 2003 | 79 | 0.010 |
Why?
| | Phosphotransferases | 1 | 2003 | 27 | 0.010 |
Why?
| | bcl-Associated Death Protein | 1 | 2003 | 8 | 0.010 |
Why?
| | Class Ib Phosphatidylinositol 3-Kinase | 1 | 2003 | 5 | 0.010 |
Why?
| | Aconitate Hydratase | 1 | 2003 | 14 | 0.010 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2003 | 153 | 0.010 |
Why?
| | Toll-Like Receptors | 1 | 2004 | 194 | 0.010 |
Why?
| | Metalloporphyrins | 1 | 2003 | 66 | 0.010 |
Why?
| | Algorithms | 1 | 2010 | 1834 | 0.010 |
Why?
| | Mice, Mutant Strains | 1 | 2003 | 299 | 0.010 |
Why?
| | Lipid Peroxidation | 1 | 2003 | 160 | 0.010 |
Why?
| | Extracellular Space | 1 | 2003 | 120 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2010 | 3403 | 0.010 |
Why?
| | Replication Protein C | 1 | 2001 | 4 | 0.010 |
Why?
| | Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2001 | 12 | 0.010 |
Why?
| | bcl-X Protein | 1 | 2001 | 45 | 0.010 |
Why?
| | Toll-Like Receptor 4 | 1 | 2004 | 276 | 0.010 |
Why?
| | Biological Transport | 1 | 2003 | 412 | 0.010 |
Why?
| | Cysteine Endopeptidases | 1 | 2001 | 73 | 0.010 |
Why?
| | Protein Kinases | 1 | 2003 | 315 | 0.010 |
Why?
| | CREB-Binding Protein | 1 | 2001 | 34 | 0.010 |
Why?
| | Transcription Factor RelA | 1 | 2001 | 85 | 0.010 |
Why?
| | Tungsten | 1 | 2001 | 30 | 0.010 |
Why?
| | Animal Feed | 1 | 2001 | 53 | 0.010 |
Why?
| | Immune Sera | 1 | 2000 | 77 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2001 | 196 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2001 | 175 | 0.010 |
Why?
| | Organ Specificity | 1 | 2000 | 312 | 0.010 |
Why?
| | Endotoxins | 1 | 2000 | 220 | 0.010 |
Why?
| | Antioxidants | 1 | 2003 | 549 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2003 | 736 | 0.010 |
Why?
| | Protein Biosynthesis | 1 | 2001 | 458 | 0.010 |
Why?
| | Intubation, Intratracheal | 1 | 2000 | 320 | 0.010 |
Why?
| | Peptides | 1 | 2001 | 995 | 0.010 |
Why?
| | Proteins | 1 | 2001 | 1021 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2010 | 11643 | 0.010 |
Why?
|
|
Arcaroli's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|